Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Thrombocythemia, Essential 1Rhabdoid Tumor 1Polycythemia Vera 1Multiple Myeloma 1Glioblastoma 1Chromosome 17 deletion 1Central Nervous System Neoplasms 1Breast Neoplasms 1

Interventions

Cyclophosphamide 12Etoposide 11Granulocyte Colony-Stimulating Factor 7Filgrastim 7Carboplatin 7etoposide phosphate 6Vincristine 5Methotrexate 5Cisplatin 5fludarabine 4Topotecan 4Thiotepa 4Stem Cell Transplantation 4Radiotherapy 4Mesna 4Melphalan 4Temozolomide 3Sirolimus 3Ifosfamide 3Busulfan 3Automobiles 3selinexor 2sargramostim 2fludarabine phosphate 2Peripheral Blood Stem Cell Transplantation 2Nivolumab 2Leucovorin 2Ipilimumab 2Hydrocortisone 2Gemcitabine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Rhabdoid Tumor × RG7388 × Clear all
NCT05952687 2024-03-27

Trial of Idasanutlin and Selinexor Therapy for Children With Progressive/Relapsed AT/RT or Extra-CNS Malignant Rhabdoid Tumors

St. Jude Children's Research Hospital

Phase 1 Withdrawn
CNS

Central Nervous System Neoplasms, Rhabdoid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡